Tuesday, August 9, 2022

Actelion says wins Japanese approval for heart and lung drug

Actelion says wins Japanese approval for heart and lung drug

TOKYO - Actelion said on Thursday theJapanese health regulator approved Opsumit, its new treatment for pulmonary arterial hypertension (PAH).

The Swiss firm's drug has already won approval in the United States and Europe. - Reuters